Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection

NCT00464893 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT00464893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00464893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection
Lead sponsor
Neovii Biotech
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
April 30, 2013
Enrollment
70 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastric cancer